Table 3.
The in-silico profiling results for isolates sequenced using MinION
| Samples* | Method | RIF | INH | EMB | PYR | STR | ETH | AMK | CAP | FLQ | PAS |
|---|---|---|---|---|---|---|---|---|---|---|---|
| por5 | DST | R | R | R | R | R | R | S | S | S | S |
| TBProfiler | R | R | R | R | R | R | S | S | S | S | |
| Mykrobe** | R | R | R | 82%R | R | – | S | S | S | – | |
| por6 | DST | R | R | R | R | R | R | R | R | R | S |
| TBProfiler | R | R | R | R | R | R | R | R | R | S | |
| Mykrobe | R | R | R | R | R | – | 82%R | 82%R | R | – | |
| por7 | DST | R | R | R | R | R | R | R | R | R | S |
| TBProfiler | R | R | R | R | R | R | S | S | R | S | |
| Mykrobe | R | 92%R | S | R | 83%R | – | S | S | 91%R | – |
DST drug susceptibility testing (R resistant, S sensitive); this table shows the percentage of replicates producing the correct result; − cannot be determined; bolded values indicate the % of replicates with DST phenotypes, where resistance mutations are not found in all replicates. Underlined values indicate where the variant is not present in software mutation library; RIF rifampicin, INH isoniazid, EMB ethambutol, PYR pyrazinamide, STR streptomycin, ETH ethionamide, AMK amikacin, CAP capreomycin, FLQ fluoroquinolones, PAS para-aminosalicylic acid. *All LAM4 strain-types or sub-lineage 4.3.4.2. **Mykrobe-Profiler TB (https://github.com/iqbal-lab/Mykrobe-predictor) implemented using its command-line version